Delving into the Latest Updates on Methazolamide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Methazolamide (JAN/USP/INN), Methenamide, Neptazaneat

+ [6]

Target

CAs

Action

inhibitors

Mechanism

CAs inhibitors(Carbonic anhydrases inhibitors)

Therapeutic Areas

Eye Diseases

Active Indication

Glaucoma

Inactive Indication-

Originator Organization

Lederle Laboratories

Active Organization-

Inactive Organization

Lederle Laboratories

Drug Highest PhaseApproved

First Approval Date

United States (26 Jan 1959),

Glaucoma

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC5H8N4O3S2

InChIKeyFLOSMHQXBMRNHR-UHFFFAOYSA-N

CAS Registry554-57-4

This paper describes the synthesis and in vitro biol. evaluation of new compounds designated as and .These compounds were synthesized by the reaction of thiazole derivative or thiadiazole derivative with urea and various aromatic aldehydes in ethanol.The structures of the synthesized compounds were checked by IR,¹H,¹³C NMR, and Mass spectroscopy.The antibacterial and antifungal activities of the compounds were evaluated against Escherichia coli (Gram-neg.), Staphylococcus aureus (Gram-pos.), and Candida albicans (fungus) using agar well diffusion, min. inhibitory concentration (MIC), and min. bactericidal/fungicidal concentration methods.The cytotoxic activities of these compounds against HT-29 and A-549 cancer cell lines were assessed in vitro by the MTT method.Our studies showed compounds and to have the most expressed antibacterial activity against S. aureus, while compounds and were the most potent against E. coli.Compounds and showed the highest antifungal activity against C. albicans, and compound showed the most potent activity against the tested cancer cell lines.

01 Feb 2025·Journal of Sleep Research

Effects of the low Fowler's sleep position and methazolamide treatment on sleep bruxism: A randomized controlled trial

Article

Author: Zhong, Zhijun ; Yao, Dongyuan ; Ouyang, Qian ; Zhang, Ling ; Liu, Xinting ; Zou, Xueliang ; Luo, Yaxing ; Li, Qi

SummaryIntracranial pressure is one of the determinants of sympathetic activities, and sleep bruxism is associated with increased sympathetic activities. This study aimed to investigate effects of the low Fowler's sleep position and methazolamide treatment on the occurrence of rhythmic masticatory muscle activities/sleep bruxism episodes in patients with sleep bruxism in a randomized controlled trial. Polysomnographic recordings were performed on the patients with sleep bruxism sleeping in the low Fowler's (15°–30°) or supine position (n = 11), and with methazolamide or placebo treatment (100 mg, 3–4 hr before bedtime, P.O., n = 9), and changes in sleep variables and heart rate variance during sleep in the low Fowler's position or with methazolamide treatment were determined. Sleep bruxism index, number of masseter muscle electromyographic bursts per hour of sleep, ratio of rhythmic masticatory muscle activities/sleep bruxism duration to the total sleep duration, index of total limb movements, index of limb movements with rhythmic masticatory muscle activities, and number of sleep bruxism clusters per hour of sleep in the low Fowler's position and after methazolamide intake were significantly smaller (p < 0.05–0.001) than those in the supine position and after placebo intake, respectively. The low‐frequency heart rate variance powers during non‐rapid eye movement sleep stage 2 (N2) in the low Fowler's position and with methazolamide treatment were significantly lower (p < 0.05) than those during sleep in the supine position and with placebo treatment, respectively. In conclusion, sleep in the low Fowler's position and methazolamide treatment were associated with significant decreases in the occurrence of rhythmic masticatory muscle activities/sleep bruxism episodes, which might be due to a reduction in intracranial pressure and sympathetic activities mainly during non‐rapid eye movement sleep stage 2.

01 Feb 2025·Bioorganic Chemistry

Synthesis, biological evaluation, and in silico studies of phenyl naphthalene-2-sulfonate derived thiosemicarbazones as potential carbonic anhydrase inhibitors

Article

Author: Talib, Rimsha ; Li, Jing ; Aftab, Hina ; Sadeghian, Nastaran ; Tariq, Hafiza Zara ; Şenol, Halil ; Alharthy, Rima D ; Eshal, Javeria ; Akram, Muhammad Safwan ; Taslimi, Parham ; Shafiq, Zahid

A series of novel phenyl naphthalene-2-sulfonate-based thiosemicarbazones (5a-v) were synthesized and evaluated for their inhibitory activity against human carbonic anhydrases I and II (hCA I and hCA II). Compounds 5d and 5p demonstrated the highest inhibitory potency, with IC₅₀ values of 4.32 ± 0.02 nM and 5.24 ± 0.03 nM for hCA I, and 3.89 ± 0.01 nM and 4.72 ± 0.01 nM for hCA II, respectively. Notably, compound 5d exhibited superior potency compared to the reference drug acetazolamide. The structure-activity relationship (SAR) analysis revealed that electron-withdrawing groups, particularly the dichlorophenyl group in 5d and 5p, enhanced inhibitory activity. Molecular docking and molecular dynamics simulations confirmed the high binding affinity of compound 5d, with docking scores of -9.7 kcal/mol for hCA I and -9.5 kcal/mol for hCA II. Stability in MD simulations further supported its potent inhibitory action. ADMET predictions suggested that compounds 5d and 5p have favorable pharmacokinetic profiles. In conclusion, phenyl naphthalene-2-sulfonate-based thiosemicarbazones, especially compound 5d, show strong potential as therapeutic agents targeting hCA I and hCA II.

100 Deals associated with Methazolamide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00655	Methazolamide	S01EC05	DB00703

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	United States	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02463357 (CTgov)	Phase 4	Altitude Sickness	148	Quercetin (Quercetin)	otyvnamlix(zqwcsvorga) = jqibsypfod fkkcmjshsy (tnyhwcobrz, pkleeebxye - qcwmujsbhx) View more	-	30 Mar 2021
				Methazolamide+Nifedipine extended release (Nifedipine+Methazolamide)	otyvnamlix(zqwcsvorga) = zkbvpfpgzc fkkcmjshsy (tnyhwcobrz, pfqlczuyar - cnwzmskiuc) View more
Abstract 2013 (AACR2019)	Not Applicable	Pancreatic Cancer	-	Methazolamide + Gemcitabine	ttyxsnkcxr(rvuwtmhgft) = anti-angiogenic potential viz. would healing, tube formation and expression of important anti-angiogenic markers like HIF1α, VEGF were profoundly modulated in MZM and combination group xutilpmwrz (yxsaubwbqw ) View more	Positive	01 Jul 2019
				Methazolamide
NCT02758470 (Pubmed \| J Appl Physiol (1985))	Phase 4	Hypoxia	13	Acetazolamide	mngufeejqg(lqgepczzgj) = vxilsicjgd mbpmfciabh (ugnzsosgux ) View more	-	01 Sep 2018
				Methazolamide	mngufeejqg(lqgepczzgj) = ckqtyilplr mbpmfciabh (ugnzsosgux ) View more
NCT01587027 (CTgov)	Phase 1	Altitude Sickness	16	Methazolamide+Aminophylline (Sequence A)	oqgokvyini(rpzcaymewr) = ppajbfsfzx qcbscjneoq (fmoisrkzju, tpudwovkwh - omxsvrkhjt)	-	09 Jun 2014
				Methazolamide+Aminophylline (Sequence B)	oqgokvyini(rpzcaymewr) = izribhdlya qcbscjneoq (fmoisrkzju, lnudzmloxv - hkpgrrlfbc)
AAO2002	Not Applicable	Stevens-Johnson Syndrome	-	Methazolamide	(yitupajrsd) = byigqbwpmd unfoqhnfve (tpdcxxhvzv ) View more	-	22 Oct 2002